Publications by authors named "Alex Eustace"

Claim this Profile
C
Chromosome centromere copy number amplification associated with exceptional response in HER2-positive metastatic breast cancer patients.
Charlotte Andrieu, Jojanneke Stoof, Dalal AlSultan, Laura Ivers, Jose Javier Berenguer Pina, Alex J Eustace

Oncogene· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cis-regulatory and long noncoding RNA alterations in breast cancer - current insights, biomarker utility, and the critical need for functional validation.
Arnau Cuy Saqués, Aracele Martinez-Mendez, John Crown, Alex Eustace

Mol Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TCHL - a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, trastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysis.
John Crown, Alex J Eustace, Denis M Collins, Maccon Keane, Linda Coate

Acta Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the phosphatidylinositol-3-kinase (PI3K) and mitogen activated protein kinase (MAPK) signalling pathways to enhance chemoradiotherapy in locally advanced rectal cancer.
Aoife Carr, Jonathan A Coulter, Julie Workman, Joanna Fay, Angela Farrelly, Alex J Eustace

Cancer Treat Res Commun· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TP53 Mutation-Specific Dysregulation of Store-Operated Calcium Entry and Apoptotic Sensitivity in Triple-Negative Breast Cancer.
Kaneez E Rabab, Paul J Buchanan, Grace Colley, Anita White, Aisling Murphy, Alex J Eustace

Cancers (Basel)· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis of carbon dots from spent coffee grounds: transforming waste into potential biomedical tools.
Yingru Zhou, Adalberto Camisasca, Sofia Dominguez-Gil, Michał Bartkowski, Keith D Rochfort, Alex J Eustace

Nanoscale· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translating Basic Science Discoveries into Clinical Advances: Highlights from the EACR-AACR-IACR 2024 Conference in Celebration of Irish Association for Cancer Research's 60th Anniversary.
Seodhna M Lynch, Cathy E Richards, Aisling Ui Mhaonaigh, Niamh Lynam-Lennon, Alex J Eustace

Cancers (Basel)· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Precision Oncology, Artificial Intelligence, and Novel Therapeutic Advancements in the Diagnosis, Prevention, and Treatment of Cancer: Highlights from the 59th Irish Association for Cancer Research (IACR) Annual Conference.
Seodhna M Lynch, Aisling B Heeran, Caoimbhe Burke, Niamh Lynam-Lennon, Alex J Eustace

Cancers (Basel)· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy.
Nicola Gaynor, Alfonso Blanco, Stephen F Madden, Barry Moran, Jean M Fletcher, Alex J Eustace

Br J Cancer· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer.
Nicola Cosgrove, Alex J Eustace, Peter O'Donovan, Stephen F Madden, Bruce Moran

NPJ Breast Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer.
Sandra Roche, Patricia Gaule, Deirdre Winrow, Nupur Mukherjee, Fiona O'Neill, Alex J Eustace

PLoS One· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Precision Medicine and Novel Therapeutic Strategies in Detection and Treatment of Cancer: Highlights from the 58th IACR Annual Conference.
Sean P Kennedy, Oliver Treacy, Emma H Allott, Alex J Eustace, Niamh Lynam-Lennon

Cancers (Basel)· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Systems Biology Approach to Investigate Kinase Signal Transduction Networks That Are Involved in Triple Negative Breast Cancer Resistance to Cisplatin.
Nupur Mukherjee, Alacoque Browne, Laura Ivers, Tapesh Santra, Mattia Cremona, Alex J Eustace

J Pers Med· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aberrant calcium signalling downstream of mutations in TP53 and the PI3K/AKT pathway genes promotes disease progression and therapy resistance in triple negative breast cancer.
Alex J Eustace, Min Jie Lee, Grace Colley, Jack Roban, Tim Downing

Cancer Drug Resist· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The novel low molecular weight MYC antagonist MYCMI-6 inhibits proliferation and induces apoptosis in breast cancer cells.
Dalal AlSultan, Emma Kavanagh, Shane O'Grady, Alex J Eustace, Alina Castell

Invest New Drugs· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.
Denis M Collins, Stephen F Madden, Nicola Gaynor, Dalal AlSultan, Marion Le Gal, Alex J Eustace

Clin Cancer Res· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A.
Laura Breen, Patricia B Gaule, Alexandra Canonici, Naomi Walsh, Denis M Collins, Alex J Eustace

Invest New Drugs· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer.
Sean P Kennedy, Michael O'Neill, Darren Cunningham, Patrick G Morris, Sinead Toomey, Alex J Eustace

Oncogene· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined targeting EGFR and SRC as a potential novel therapeutic approach for the treatment of triple negative breast cancer.
Alexandra Canonici, Alacoque L Browne, Mohamed F K Ibrahim, Kevin P Fanning, Sandra Roche, Alex J Eustace

Ther Adv Med Oncol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells.
Patricia Gaule, Nupur Mukherjee, Brendan Corkery, Alex J Eustace, Kathy Gately

Cancers (Basel)· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH).
Damien Coté, Alex Eustace, Sinead Toomey, Mattia Cremona, Malgorzata Milewska

PLoS One· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
Alex J Eustace, Neil T Conlon, Martina S J McDermott, Brigid C Browne, Patrick O'Leary

BMC Cancer· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells.
Alexandra Canonici, Zulfiqar Qadir, Neil T Conlon, Denis M Collins, Neil A O'Brien, Alex J Eustace

Invest New Drugs· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frequency, impact and a preclinical study of novel gene family mutations in HER2-positive breast cancer.
Naomi Elster, Sinead Toomey, Yue Fan, Mattia Cremona, Clare Morgan, Alex Eustace

Ther Adv Med Oncol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers.
Malgorzata Milewska, Mattia Cremona, Clare Morgan, John O'Shea, Aoife Carr, Alex J Eustace

Ther Adv Med Oncol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis